For scenario-based sensitivity analyses, we varied the uptake of anti-PD-(L)1 agents, the target population, the time to launch of anti-PD-(L)1 agents, the capacity for retreatment with anti-PD-(L)1 agents, and the inclusion of various subgroups of cancer. Here, CD274 is linked to cancer.